

12 June 2019

**Our Ref:** RFI 28890

Dear

**Freedom of Information Act 2000  
Information in Relation to Cancer Treatments**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 21 May 2019.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital ([informationgovernance@setrust.hscni.net](mailto:informationgovernance@setrust.hscni.net)) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

---

**Rebecca Kelly**  
**Information Governance Assistant**

**Q1. Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following:**

- A1. Paclitaxel - 0  
 Gemcitabine - 0 (on single agent Gemcitabine)  
 Osimertinib - 2  
 Carboplatin and Pemetrexed - 13  
 Cisplatin and Pemetrexed - 0  
 Pembrolizumab monotherapy - 4  
 Pembrolizumab in combination - 0  
 Ateolizumab - 2  
 Nivolumab - 0  
 Other active systemic anti-cancer therapy – 32

**Q2. Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Non-Small Cell Lung cancer patients?**

- A2. Yes. SMP2 Stratified Medicine Programme, Cancer Research UK Stratified Medicine.

**Q3. If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?**

- A3. There is currently a total recruitment of 29 patients taking part in the trial mentioned in A2.

**Q4. Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:**

- A4. Cetuximab not in combination with FOLFIRI or FOLFOX - 3  
 Cetuximab in combination with FOLFIRI - 3  
 Cetuximab in combination with FOLFOX - 2  
 Panitumumab not in combination with FOLFIRI or FOLFOX - 0  
 Panitumumab in combination with FOLFIRI - 0  
 Panitumumab in combination with FOLFOX - 0  
 Nivolumab - 0  
 Aflibercept - 0  
 Bevacizumab - 0  
 Ramucirumab - 0  
 Regorafenib - 0  
 Sorafenib - 0  
 Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU) – 85

**Q5. Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal Cancer patients?**

A5. Yes.

- NSCCG National Study Of Colorectal Cancer Genetics (OPEN)
- CReST 2 Colorectal Stenting Trial 2 - Uncovered and Covered Endoluminal Stenting in the acute management of obstructing colorectal cancer in the palliative setting (OPEN)
- ADD ASPIRIN A Phase III, Double-Blind, Placebo-Controlled Randomised Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival after Primary Therapy in Common Non-Metastatic Solid Tumours (PENDING)

**Q6. If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?**

A6. NSCCG has a total recruitment of 140 patients  
CReST2 has a total recruitment of 10 patients

**Q7. Within your Health Trust how many patients are currently (within the past 6 months available) being treated with the following:**

A7. Under the assumption that this is Metastatic Urothelial Carcinoma:

- Cisplatin single agent - 0
- Cisplatin in combination with another agent - 0
- Carboplatin single agent - 0
- Carboplatin in combination with another agent - 0
- Nivolumab - 0
- Pembrolizumab - 0
- Atezolizumab - 0
- Other active systemic anti-cancer therapy - 0

**Q8. Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients?**

A8. No trials currently available for this patient population within the Trust or within the wider Northern Ireland Cancer Trials Network (NICTN) of studies/trials.

**Q9. If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?**

A9. Not applicable.